European Medicines Agency decision
P/0151/2023

of 24 April 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline), (EMEA-002612-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0151/2023

of 24 April 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline), (EMEA-002612-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by ASK Pharmaceuticals GmbH on 29 June 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 March 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline), solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A waiver for 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline), solution for injection/infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to ASK Pharmaceuticals GmbH (ASK), 35 Heimeranstr., D-80339 – Munich, Germany.
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver
EMEA-002612-PIP02-22

Scope of the application

Active substance(s):
2-amino-5-(carbamylamino)pentanoic acid (L-citrulline)

Invented name and authorisation status:
See Annex II

Condition(s):
Treatment of sickle cell disease

Pharmaceutical form(s):
Solution for injection/infusion

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
ASK Pharmaceuticals GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, ASK Pharmaceuticals GmbH submitted for agreement to the European Medicines Agency on 29 June 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 16 August 2022.

Supplementary information was provided by the applicant on 30 January 2023. The applicant proposed modifications to the paediatric investigation plan.
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   • to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   
   • to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

   This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

1.1. Condition:

Treatment of sickle cell disease

The waiver applies to:
- the paediatric population from birth to less than 2 years of age;
- solution for injection/infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of sickle cell disease

2.1.1. Indication(s) targeted by the PIP

Treatment of vaso-occlusive crisis in children with sickle cell disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection/infusion

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Clinical studies</td>
<td>Study 1 (CIT-SCD-001-01) 2-part study with an open-label, dose escalation phase (part 1) to identify the optimum dosing regimen(s) for part 2, a double-blind, randomised, placebo-controlled, efficacy, adaptive design study of L-citrulline as add-on to standard of care in children and adolescents from 6 years to less than 18 years of age (and adults). Study 2 2-part study with an open-label, dose escalation phase (part 1) to identify the optimum dosing regimen(s) for part 2, a double-blind, randomised, placebo-controlled, efficacy, adaptive design study of L-citrulline as add-on to standard of care in children and adolescents from 6 years to less than 18 years of age (and adults).</td>
</tr>
</tbody>
</table>
citrulline as add-on to standard of care in children from 2 years to less than 6 years of age.

<table>
<thead>
<tr>
<th>Modelling and simulation studies</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other studies</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Extrapolation plan</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

### 3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety/efficacy issues in relation to paediatric use:</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By March 2025</td>
</tr>
<tr>
<td>Deferral for one or more measures contained in the paediatric investigation plan:</td>
<td>No</td>
</tr>
</tbody>
</table>
Annex II

Information about the authorised medicinal product
**Information provided by the applicant:**

The product is not authorised anywhere in the European Community.